Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424486 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL12463068 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL22631620 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL17399388 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL23100945 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL756764 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL23101821 | 1.00 | CYP2C9 (0.57) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL13243111 | 0.88 | LMNA (0.46) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL16727365 | 0.88 | MAPK1 (0.46) | CYP2C9LMNASLC6A2SLC6A3CHRM1 | |
| SCHEMBL14310687 | 0.88 | MAPK1 (0.46) | CYP2C9LMNASLC6A2SLC6A3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | claimed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | claimed |
| US-4432983-A | GASTRIC ACID INHIBITORS | RESEARCH CORPORATION (US) | 1984-02-21 | — | — | US | claimed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4397661-A1 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-07-10 | — | — | EP | disclosed |
| EP-3967695-B1 | 1-(7-(QUINAZOLIN-4-YL)-2,7-DIAZASPIRO[3.5]NONAN-2-YL)PROP-2-EN-1-ONE DERIVATIVES AS KRAS INHIBITORS FOR THE TREATMENT OF CANCER | BETTA PHARMACEUTICALS CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| WO-2024009232-A1 | SUBSTITUTED N-(PYRIDIN-2-YL)ACETAMIDE DERIVATIVES AS CDK12/13 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| EP-1429811-A1 | THEURAPEUTIC TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003099783-A2 | TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003015830-A1 | THEURAPEUTIC TROPANE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0996619-A1 | TROPANE ANALOGS AND METHODS FOR INHIBITION OF MONOAMINE TRANSPORT | ORGANIX, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999002526-A1 | TROPANE ANALOGS AND METHODS FOR INHIBITION OF MONOAMINE TRANSPORT | ORGANIX, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5770180-A | COCAINE | ORGANIX, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0309424-A2 | New amidino derivatives | ISTITUTO DE ANGELI S.p.A. (IT) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | CYP2C9 4293/4885LMNA 1356/4885SLC6A2 3747/4885 |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | CYP2C9 87/4885LMNA 1905/4885SLC6A2 2931/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CYP2C9 1658/4885LMNA 1966/4885SLC6A2 100/4885 |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | CYP2C9 1835/4885LMNA 1267/4885SLC6A2 4477/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CYP2C9 10/4885LMNA 1976/4885SLC6A2 885/4885 |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | CYP2C9 3015/4885LMNA 1983/4885SLC6A2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.